Innosurge Biologics A/S: Financial statements 2023
CVR: 38768964
Innosurge Biologics A/S (CVR 38768964) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 2,077,814 and a net result of DKK 406,817 compared with DKK 489,687 the year before. That is a decrease of 4.8% compared with the year before. Equity amounted to DKK 1,732,886. The solvency ratio was 36.9%. The company had 2 employees in the financial year.
- Gross Profit
- 2,077,814 kr.
- Profit/Loss
- 406,817 kr.
- Equity
- 1,732,886 kr.
- Total Assets
- 4,696,208 kr.
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 2.1 mio. | 407 t. | 1.7 mio. | 2 |
| 2022 | - | 2.2 mio. | 490 t. | 1.3 mio. | 3 |
| 2021 | - | 993 t. | -613 t. | 836 t. | 3 |
| 2020 | - | -695 t. | -2.6 mio. | 1.4 mio. | 3 |
| 2019 | - | 1.2 mio. | 290 t. | 2 mio. | 2 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of October 1, 2023, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of Innosurge Biologics A/S.
As of October 1, 2023, Kvist & Jensen Statsautoriseret Revisionspartnerselskab has stepped down as auditor of Innosurge Biologics A/S.
Innosurge Biologics A/S has published its annual report for 2022. Gross profit came to DKK 2,183,245, and the net result was DKK 489,687.
About Innosurge Biologics A/S
Innosurge Biologics A/S is a Danish company of the type Aktieselskab based in Randers NV, founded in 2017. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The management consists of Peter Møller Lassen. The company is owned by CMA HOLDING RANDERS ApS. The company has 1 employee. In 2025, the company reported a gross profit of DKK 4,455,235 and a net result of DKK 1,662,593 compared with DKK 251,617 the year before. Equity amounted to DKK 2,897,096.
